Altogen Labs Archives

Author Archives: Altogen Labs

Toxicology IND Preclinical Research Services

Toxicology IND Preclinical Research Services

Altogen Labs, a preclinical CRO, provides essential safety and efficacy testing for novel medicines (GLP-compliant pharm/tox assays per FDA IND requirements). Company works with renowned academic research organizations and pharma/biotech industry to reduce GLP studies timelines and costs while maintaining high quality and GLP standards. Altogen Labs preclinical CRO services includes efficacy xenograft studies (over 100 validated xenografts), assay development (ELISA, in vivo RNAi, biodistribution, etc) and full spectrum of pharm/tox safety assays.

Pharmacology and toxicology testing performed both in vitro and in vivo, ensuring safety and effectiveness that is of utmost importance for any novel medical test compound. Toxicology studies are essential in determining safe dosage amounts, as well as understanding mechanism of action and ways of drug delivery for humans. Standard toxicology tests to assess toxicology profile of the novel medical compound include: acute toxicity (short-term toxicological effects), sub-chronic toxicity (repeated administration of small doses of the test compound), and chronic toxicology (adverse effects following repeated exposure for long period of time). Pharmacology PK/PD tests performed to supplement safety data with pharmacokinetics, dynamics, and metabolism analysis.

While novel test compound efficiency and safety testing can be standard, Altogen Labs offers a number of custom preclinical services to understand the mechanism of action of test compound. These assays include the biomarker screening, gene expression analysis (both protein and mRNA expression levels), gene silencing functional assays (RNAi library screening), correlation of PK/PD assays with tissue biodistribution and hematological analysis to predict and identify possible adverse effects in humans. Altogen Labs perform all in vivo laboratory services under IACUC regulated guidelines and committed to the highest standards of laboratory animal welfare. The variety of oncology, pharmacology, and biotechnology services provided by Altogen Labs are all executed timely, with high quality, and at highly competitive prices to ensure the success of the project and guarantee that client expectations are met.

About Altogen Labs

Altogen Labs is a GLP-compliant contract research laboratory (preclinical CRO) located in Austin, TX. Company provides all types of pharmacology and toxicology preclinical studies to determine the safety of novel medical test compounds and evaluate the therapeutic effectiveness of a potential drug candidate prior to starting clinical trials.


Altogen Labs
11200 Manchaca Road, Suite 203
Austin, TX, 78748
(512) 433-6177

Altogen Laboratory Testing of Known Compounds for Cancer Treatment Efficacy

Sodium dichloroacetate (DCA) has been investigated as a novel cancer therapy since 2007 when Bonnet et al published research study demonstrating the efficacy of DCA in treating human cancers by inhibition of mitochondrial pyruvate dehydrogenase kinase (PDK). Altogen Labs, an Austin-based biotechnology and preclinical research company, performed an independent study exploring potential novel and accessible… Continue Reading

Characterizing Novel Inhibitor Activity

Publication [Download PDF]: Alexandra Tyulyandina, Daniel Harrison, Wei Yin, et al.  Invest New Drugs 35: 127–133. doi: 10.1007/s10637-016-0400-5 Based on data from 2013-2015, about 38% of the population will be diagnosed with some type of cancer during their lifetime, and there is an ongoing need for improved treatment techniques. Some chemotherapy agents are specific to… Continue Reading

Altogen Xenograft Model in a KRAS Pancreatic Adenocarcinoma Study

Publication [Download PDF]: KRAS mutant allele-specific expressionknockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex by Donald D. Rao et al. PLOS ONE Pancreatic cancer is notorious for its poor prognosis caused by early metastasis potential. While cancer biology has obtained a deeper understanding of biochemical, micro-environmental, genetic and epigenetic occurrences in… Continue Reading

Altogen Labs in Therapeutic Oligonucleotide Patent Application

Dnai for the modulation of genes Aberrant gene expression, for example overexpression or expression of mutant genes and proteins, is the root cause of many diseases. Cancer is a result of aberrant cellular signaling that causes uncontrolled growth and proliferation; as a complex disease, combination proteins involving angiogenesis, epithelial to mesenchymal transition, tumor suppression, cell… Continue Reading

Acute Myeloid Leukemia (AML) Research Study

Publication [Download PDF]: MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood. 118(7):1899-902. doi: 10.1182/blood-2010-09-306258 Acute myeloid leukemia (AML) is a rapidly progressing cancer characterized by the abnormal buildup of myeloid cells that interfere with normal blood cell (red, white and platelet) function. There are certain genetic markers, for example monosomy 7 (–7) and… Continue Reading

Altogen Labs offers in vivo imaging services for drug development and biodistribution studies: Orthotopic glioma xenograft model

Altogen Labs provides in vivo imaging services for drug development and biodistribution studies: U87 orthotopic glioma xenograft animal model study  by Altogen Labs, 11200 Manchaca Rd, Suite 203 Austin TX 78748 USA Download full text PDF:  Introduction In vivo imaging has emerged as a critical tool in visualization in preclinical research studies related to the development… Continue Reading

Altogen Labs in the Investigation of miRNA expression of Acute Myeloid Leukemia

Publication [Download PDF]: Dmitriy Ovcharenko, Friedrich Stolzel, David Poitz, Fernando Fierro, Markus Schaich, Andreas Neubauer, Kevin Kelnar, Timothy Davison, Carsten Muller-Tidow, Christian Thiede, Martin Bornhauser, Gerhard Ehninger, David Brown, and Thomas Illmer. Experimental Hematology 2011; 39:1030–1042 Acute myeloid leukemia (AML) is a cancer that affects hematopoietic stem cells and often results in the accumulation of… Continue Reading

Alofanib Preclinical Research Study

Publication [Download PDF]: Tyulyandina, A., Harrison, D., Yin, W. et al. Invest New Drugs (2017) 35: 127. Ovarian cancer is notorious for its poor prognosis; five-year survival rates for are 40% and 18% for stages III and IV, respectively. Ovarian cancer classifications are defined by the origin cell types and include papillary serous histology,… Continue Reading

Xenograft Models for Preclinical Research: From Translational Studies to Clinical Trials

AUSTIN, TX, December 17, 2018 Altogen Labs, a biotechnology laboratory focused on the development of innovative cancer therapeutics, today announced the addition of new CDX models (MDA-MB-157, MDA-MB-453, U87, and OVCAR-3). The addition of these xenograft models further increases Altogen Labs’ product line in breast and ovarian cancer, as well as glioblastoma to 89 CDX,… Continue Reading